S-8 1 d143568ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on March 10, 2021

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Oncorus, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   47-3779757
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)

50 Hampshire Street, Suite 401

Cambridge, Massachusetts 02139

(Address of principal executive offices) (Zip code)

Oncorus, Inc. 2020 Equity Incentive Plan

(Full title of the plan)

Theodore (Ted) Ashburn, M.D., PhD.

President and Chief Executive Officer

Oncorus, Inc.

50 Hampshire Street, Suite 401

Cambridge, Massachusetts 02139

Tel: (857) 320-6400

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

 

Marc A. Recht

Brian F. Leaf

Courtney T. Thorne

Cooley LLP

500 Boylston Street

Boston, Massachusetts 02116

(617) 937-2300

  

John McCabe

Chief Financial Officer, Treasurer and Secretary

Oncorus, Inc.

50 Hampshire Street, Suite 401

Cambridge, Massachusetts 02139

(857) 320-6400

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
     Emerging growth company   ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of Securities

To Be Registered

   Amount
To Be
Registered(1)		   Proposed
Maximum
Offering Price
Per Share		   Proposed
Maximum
Aggregate
Offering Price		  

Amount of

Registration Fee

Common Stock, par value $0.0001 per share

   1,130,896(2)   $13.58(3)   $15,357,567.68   $1,675.51

 

 

(1)

Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock, par value $0.0001 ( “Common Stock”) that become issuable under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction that results in an increase in the number of the Registrant’s outstanding shares of Common Stock.

(2)

Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2020 Plan on January 1, 2021, pursuant to an “evergreen” provision contained therein. Pursuant to such provision, the number of shares of Common Stock reserved for issuance under the 2020 Plan will automatically increase on January 1st of each fiscal year, starting on January 1, 2021 and ending on and including January 1, 2030, in an amount equal to 5.0% of the total number of shares of the Registrant’s Common Stock outstanding on the last day of the fiscal year prior to the date of such automatic increase or a lesser number of shares determined by the Registrant’s board of directors (or authorized committee thereof).

(3)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) promulgated under the Securities Act. The offering price per share and the aggregate offering price are based upon $13.58, which is the average of the high and low prices of the Registrant’s Common Stock as reported on the Nasdaq Global Market on March 5, 2021.

 

 

 

PART I

EXPLANATORY NOTE

The Registrant is filing this Registration Statement on Form S-8 for the purpose of registering 1,130,896 shares of the Registrant’s common stock, par value $0.0001 (the “Common Stock”), issuable to eligible persons under the Registrant’s 2020 Equity Incentive Plan (the “2020 Plan”), which Common Stock is in addition to the shares of Common Stock registered on the Registrant’s Form S-8 filed on October 9, 2020 (File No. 333-249425) (the “Prior Registration Statement”).

This Registration Statement relates to securities of the same class as that to which the Prior Registration Statement relates, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement, to the extent relating to the registration of Common Stock issuable under the 2020 Plan, are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

PART II

 

ITEM 8.

EXHIBITS

 

Exhibit
Number		     

Description

    Incorporated by Reference  
   Schedule
Form		      File
Number		      Exhibit    Filing Date  
  4.1      Amended and Restated Certificate of Incorporation, as currently in effect.      8-K        001-39575      3.1      October 6, 2020  
  4.2      Amended and Restated Bylaws, as currently in effect.      8-K        001-39575      3.2      October 6, 2020  
  4.3      Form of Common Stock Certificate.      S-1/A        333-248757      4.2      September 28, 2020  
  5.1 *     Opinion of Cooley LLP.            
  23.1 *     Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.            
  23.2 *     Consent of Cooley LLP (included in Exhibit 5.1).            
  24.1 *     Power of Attorney (included on the signature page of this Form S-8).            
  99.1      2020 Equity Incentive Plan.      S-1/A        333-248757      10.5      September 28, 2020  
  99.2      Form of Stock Option Grant Notice and Option Agreement for the 2020 Equity Incentive Plan.      S-1/A        333-248757      10.6      September 28, 2020  
  99.3      Form of Restricted Stock Unit Grant Notice and Restricted Stock unit Award Agreement for the 2020 Equity Incentive Plan.      S-8        333-249425      4.9      October 9, 2020  

 

*

Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on this 10th day of March, 2021.

 

ONCORUS, INC.
By:  

/s/ Ted Ashburn

  Name: Theodore (Ted) Ashburn, M.D., Ph.D.
  Title: President, Chief Executive Officer and Director

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Theodore (Ted) Ashburn, M.D., PhD. and John McCabe, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, ae amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Name

   

Position

   

Date

/s/ Ted Ashburn

Theodore (Ted) Ashburn, M.D., Ph.D.

   

President, Chief Executive Officer and Director

(Principal Executive Officer)

    March 10, 2021

/s/ John McCabe

John McCabe

   

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

    March 10, 2021

/s/ Mitchell Finer

Mitchell Finer, Ph.D.

    Executive Chairman    March 10, 2021

/s/ Scott Canute

    Director    March 10, 2021
Scott Canute      

/s/ Luke Evnin

Luke Evnin, Ph.D.

    Director    March 10, 2021

/s/ Mary Kay Fenton

Mary Kay Fenton

    Director    March 10, 2021

/s/ Robert Kirkman

Robert Kirkman, M.D.

    Director    March 10, 2021

/s/ Briggs Morrison

Briggs Morrison, M.D.

    Director    March 10, 2021

/s/ Spencer Nam

Spencer Nam

    Director    March 10, 2021

/s/ Cameron Wheeler

Cameron Wheeler, Ph.D.

    Director    March 10, 2021